IL126161A0 - Method for treating autism - Google Patents

Method for treating autism

Info

Publication number
IL126161A0
IL126161A0 IL12616196A IL12616196A IL126161A0 IL 126161 A0 IL126161 A0 IL 126161A0 IL 12616196 A IL12616196 A IL 12616196A IL 12616196 A IL12616196 A IL 12616196A IL 126161 A0 IL126161 A0 IL 126161A0
Authority
IL
Israel
Prior art keywords
treating autism
treating
autism
olanzapine
administering
Prior art date
Application number
IL12616196A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Priority to IL13950696A priority Critical patent/IL139506A0/xx
Publication of IL126161A0 publication Critical patent/IL126161A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Transplanting Machines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Luminescent Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
IL12616196A 1996-03-11 1996-12-04 Method for treating autism IL126161A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL13950696A IL139506A0 (en) 1996-03-11 1996-12-04 Method for treating autism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11
PCT/US1996/019576 WO1997033585A1 (en) 1996-03-11 1996-12-04 Method for treating autism

Publications (1)

Publication Number Publication Date
IL126161A0 true IL126161A0 (en) 1999-05-09

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12616196A IL126161A0 (en) 1996-03-11 1996-12-04 Method for treating autism

Country Status (19)

Country Link
EP (1) EP0946179B1 (de)
JP (1) JP2000506860A (de)
KR (1) KR19990087715A (de)
CN (1) CN1213970A (de)
AT (1) ATE249832T1 (de)
AU (1) AU709181B2 (de)
BR (1) BR9612552A (de)
CA (1) CA2248741A1 (de)
CZ (1) CZ290498A3 (de)
DE (1) DE69630055T2 (de)
EA (1) EA000768B1 (de)
ES (1) ES2206614T3 (de)
HU (1) HUP9903688A3 (de)
IL (1) IL126161A0 (de)
NO (1) NO984197L (de)
NZ (1) NZ324615A (de)
PL (1) PL328948A1 (de)
TR (1) TR199801798T2 (de)
WO (1) WO1997033585A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348455B1 (en) 1998-11-23 2002-02-19 Sepracor Inc. Desmetylolanzapine compositions and methods
CA2352611A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU757870B2 (en) * 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
AU2013293167B2 (en) 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
DK3058371T3 (da) 2013-10-14 2021-08-02 Univ Indiana Res & Tech Corp Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
ES2206614T3 (es) 2004-05-16
CA2248741A1 (en) 1997-09-18
DE69630055D1 (de) 2003-10-23
EA199800821A1 (ru) 1999-02-25
HUP9903688A3 (en) 2001-12-28
ATE249832T1 (de) 2003-10-15
NO984197L (no) 1998-11-03
BR9612552A (pt) 1999-07-20
AU1150197A (en) 1997-10-01
DE69630055T2 (de) 2004-06-03
EP0946179A1 (de) 1999-10-06
PL328948A1 (en) 1999-03-01
TR199801798T2 (xx) 1998-12-21
NO984197D0 (no) 1998-09-11
NZ324615A (en) 2000-08-25
EP0946179B1 (de) 2003-09-17
CN1213970A (zh) 1999-04-14
AU709181B2 (en) 1999-08-26
EA000768B1 (ru) 2000-04-24
WO1997033585A1 (en) 1997-09-18
CZ290498A3 (cs) 1999-10-13
EP0946179A4 (de) 2000-04-19
HUP9903688A2 (hu) 2000-03-28
KR19990087715A (ko) 1999-12-27
JP2000506860A (ja) 2000-06-06

Similar Documents

Publication Publication Date Title
AP1401A (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic- depressive bipolar disorder.
ZA976562B (en) Isobutylgaba and its derivatives for the treatment of pain.
DE69711078T2 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
ZA947783B (en) Method of treating depressed reticuloendothelial system function
PL328948A1 (en) Autism treating method
MX9805064A (es) Uso de 2-metil-4-(4-metil-1-piperazinil)-1oh-tieno[2,3-b][1,5]benzo diazepina.
PL328924A1 (en) Method of treating abuse of substances
PL328949A1 (en) Method of treatng excessive aggression
AU5434899A (en) Cancer treatment
EA199800818A1 (ru) Способ лечения бессонницы
UA27148C2 (uk) Спосіб лікуваhhя гострого пієлоhефриту
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
SI0825857T1 (en) Use of gabapentin and its derivatives in the treatment of mania and bipolar disorder
UA10259A (uk) Протинабряковий лікарський препарат "нейрополіосм"
UA36261A (uk) Спосіб лікування простої шизофренії з суїцидальною поведінкою
GB2322800A (en) Use of D-Arginine and/or L-Arginine to remove or block toxic carbonyls and/or dicarbonyls